Magnetic Haemofiltration is a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. We have the ambition to become a global player, providing hospitals with a new tool to tackle some of mankind’s most serious diseases.

Keep In Touch

A spin-out from University College London, MediSieve is a multi-award-winning biotech startup. The company has raised a total of £4M in equity funding and won grants worth a total of over £4M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. In December 2020 MediSieve secured a £1.6M grant from the UKRI to support pivotal clinical trials, which are due to start in Q2 2022.

Our multidisciplinary team has experience across various fields of science and technology development.

 

MediSieve Announces First Volunteer Successfully Enrolled in Phase 1 Clinical Study

MediSieve Announces First Volunteer Successfully Enrolled in Phase 1 Clinical Study
July 08, 2022

Radboud University Medical Center is Conducting Safety Evaluation of MediSieve’s Magnetic Haemofiltration System for the Treatment of Acute Hyperinflammation.
MediSieve at Industry Events In June 2022

MediSieve at Industry Events In June 2022
June 29, 2022

MediSieve, a London based biotech startup, has been busy presenting and demonstrating its technology at industry events as well as connecting with fellow scientists throughout June.